Valter Silva Monteiro
he/him/his
Postdoctoral AssociateAbout
Research
Publications
2026
Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study
Crandell J, Fantin R, de Araújo L, Lawres L, Pischel L, Monteiro V, Conde L, Kottkamp A, Samanovic M, Cordeiro R, Póvoas D, Melo M, Castineiras T, Vale A, Yildirim I, Mulligan M, de Almeida L, Omer S, Coelho C, Lucas C. Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational study. The Lancet Infectious Diseases 2026 PMID: 42314719, DOI: 10.1016/s1473-3099(26)00173-8.Peer-Reviewed Original ResearchMVA-BNcontrol cohortvaccinated cohortUS National Institutesplasma samplesmonkeypox virusneutralising activityno historyvaccina virusobservational studyantibody-based countermeasurescross-clade immunitypolyclonal plasma antibodiessmallpox vaccine Dryvaxoutbreak of monkeypox virusmonkeypox virus infectionantibody bindingvaccine-induced immunitythreshold of positivitymonkeypox virus cladesclade IAplaque reduction neutralisation testUS National Institutes of Healthantigen levelsMPXV infection
2025
Paroxetine attenuates sepsis by preserving the expression of the G protein-coupled chemokine receptor CXCR2 on neutrophils
Galant L, de Fátima Borges V, de Almeida Augusto P, Rodrigues F, Cebinelli G, Duarte D, Monteiro V, Batah S, da Costa-Neto C, Fabro A, Pupo A, Dal-Pizzol F, Cunha T, Alves-Filho J, Kanashiro A, Cunha F. Paroxetine attenuates sepsis by preserving the expression of the G protein-coupled chemokine receptor CXCR2 on neutrophils. International Immunopharmacology 2025, 165: 115475. PMID: 40913860, DOI: 10.1016/j.intimp.2025.115475.Peer-Reviewed Original ResearchA modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity
Fang Z, Monteiro V, Oh C, Janabi K, Romero L, Ahsan N, Yang L, Peng L, DiMaio D, Lucas C, Chen S. A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity. Nature Biomedical Engineering 2025, 10: 501-516. PMID: 40855125, DOI: 10.1038/s41551-025-01478-6.Peer-Reviewed Original Researchmodular vaccine platformcell surface translocationimmune responsempox virusvaccine platformmRNA vaccinesvaricella zoster virus glycoproteinlethal viral challengedevelopment of mRNA vaccinesinsufficient immune responseantigen expressionproteins E6surface expressionmRNA immunogenicitymultiple cell linesviral challengeantigenmultiple antigenscell linesantigenic epitopeschimeric antigenvirus glycoproteinimmunogenicitymRNAsurface translocationImpact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID
Grady C, Bhattacharjee B, Silva J, Jaycox J, Lee L, Silva Monteiro V, Sawano M, Massey D, Caraballo C, Gehlhausen J, Tabachnikova A, Mao T, Lucas C, Peña-Hernandez M, Xu L, Tzeng T, Takahashi T, Herrin J, Güthe D, Akrami A, Assaf G, Davis H, Harris K, McCorkell L, Schulz W, Griffin D, Wei H, Ring A, Guan L, Dela Cruz C, Krumholz H, Iwasaki A. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. Communications Medicine 2025, 5: 163. PMID: 40346201, PMCID: PMC12064684, DOI: 10.1038/s43856-025-00829-3.Peer-Reviewed Original Researchspike protein-specific IgGprotein-specific IgGself-antigensimmune response to COVID-19 vaccinationCOVID-19 vaccineantibody responseresponse to COVID-19 vaccinationT cell expansionSARS-CoV-2-specific antibody responsesassociated with no improvementlong COVIDassociated with symptom improvementchest paincirculating cytokinesimmune phenotypeprospective studyimmune featurestransient improvementprimary seriesvaccine doseherpes virusimmune responsesymptom improvementsignificant elevationimpact of COVID-19 vaccinationThe impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study
Crandell J, Monteiro V, Pischel L, Fang Z, Conde L, Zhong Y, Lawres L, de Asis G, Maciel G, Zaleski A, Lira G, Higa L, Breban M, Vogels C, Caria J, Pinto A, Almeida V, Maltez F, Cordeiro R, Póvoas D, Grubaugh N, Aoun-Barakat L, Grifoni A, Sette A, Castineiras T, Chen S, Yildirim I, Vale A, Omer S, Lucas C. The impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study. The Lancet Microbe 2025, 6: 101098. PMID: 40311645, DOI: 10.1016/j.lanmic.2025.101098.Peer-Reviewed Original ResearchT cellsantigenic distancempox virusbreadth of immune responsessmallpox vaccinethird-generation smallpox vaccineimmune responseobservational studycross-reactive immune responsesT cell cross-reactivityT cell memoryT cell responsesimmune memory responsevaccina viruscross-neutralising activityFc-mediated functionsmucosal humoral responsesvirus neutralisation titrescross-reactive responsescross-protectioncross-protective immunitycowpox virusneutralising antibody titresantibody effector functionseffector functions
2024
Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract
Mao T, Kim J, Peña-Hernández M, Valle G, Moriyama M, Luyten S, Ott I, Gomez-Calvo M, Gehlhausen J, Baker E, Israelow B, Slade M, Sharma L, Liu W, Ryu C, Korde A, Lee C, Monteiro V, Lucas C, Dong H, Yang Y, Initiative Y, Gopinath S, Wilen C, Palm N, Dela Cruz C, Iwasaki A, Vogels C, Hahn A, Chen N, Breban M, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Grubaugh N. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2319566121. PMID: 38648490, PMCID: PMC11067057, DOI: 10.1073/pnas.2319566121.Peer-Reviewed Original ResearchConceptsinterferon-stimulated genesrespiratory infectionsstrains of influenza A virustreatment of respiratory viral infectionsrespiratory virus infectionsinfluenza A virusmouse model of COVID-19respiratory viral infectionsneomycin treatmentexpression of interferon-stimulated genesupper respiratory infectioninterferon-stimulated gene expressionlower respiratory infectionsbroad spectrum of diseasesadministration of neomycinrespiratory viral diseasesdisease to patientsupper respiratory tractintranasal deliverycongenic miceintranasal applicationnasal mucosasevere acute respiratory syndrome coronavirus 2acute respiratory syndrome coronavirus 2A virus
2023
Distinguishing features of long COVID identified through immune profiling
Klein J, Wood J, Jaycox J, Dhodapkar R, Lu P, Gehlhausen J, Tabachnikova A, Greene K, Tabacof L, Malik A, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott I, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng T, Xu L, Geraghty A, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick J, Kaminski N, Omer S, Krumholz H, Guan L, Dela Cruz C, van Dijk D, Ring A, Putrino D, Iwasaki A. Distinguishing features of long COVID identified through immune profiling. Nature 2023, 623: 139-148. PMID: 37748514, PMCID: PMC10620090, DOI: 10.1038/s41586-023-06651-y.Peer-Reviewed Original ResearchConceptslong COVIDSARS-CoV-2infection syndromeexaggerated humoral responsesoluble immune mediatorsEpstein-Barr viruspost-exertional malaisecross-sectional studyhigher antibody responseimmune mediatorsimmune phenotypingimmune profilinghumoral responseantibody responselymphocyte populationsCOVID statusunbiased machinecortisol levelsLC statusrelevant biomarkersviral pathogenssyndromeCOVIDfuture studiesbiological featuresCytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis
Barmada A, Klein J, Ramaswamy A, Brodsky N, Jaycox J, Sheikha H, Jones K, Habet V, Campbell M, Sumida T, Kontorovich A, Bogunovic D, Oliveira C, Steele J, Hall E, Pena-Hernandez M, Monteiro V, Lucas C, Ring A, Omer S, Iwasaki A, Yildirim I, Lucas C. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. Science Immunology 2023, 8: eadh3455-eadh3455. PMID: 37146127, PMCID: PMC10468758, DOI: 10.1126/sciimmunol.adh3455.Peer-Reviewed Original ResearchConceptsmRNA vaccinesSARS-CoV-2 mRNA vaccinesSARS-CoV-2 mRNA vaccinationC-reactive protein levelsB-type natriuretic peptideperipheral blood mononuclear cellscardiac tissue inflammationDeep immune profilingserum soluble CD163vaccine-associated myocarditiscohort of patientsblood mononuclear cellscytotoxic T cellslate gadolinium enhancementhypersensitivity myocarditiselevated troponinmRNA vaccinationimaging abnormalitiesNK cellsimmune profilingkiller cellsmyeloid responsenatriuretic peptidehumoral mechanismsinflammatory cytokinesEnhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
Moriyama M, Lucas C, Monteiro V, Initiative Y, Iwasaki A, Chen N, Breban M, Hahn A, Pham K, Koch T, Chaguza C, Tikhonova I, Castaldi C, Mane S, De Kumar B, Ferguson D, Kerantzas N, Peaper D, Landry M, Schulz W, Vogels C, Grubaugh N. Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2221652120. PMID: 37036977, PMCID: PMC10120007, DOI: 10.1073/pnas.2221652120.Peer-Reviewed Original ResearchConceptsMHC-I expressionbreakthrough infectionssevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsmajor histocompatibility complex class I expressioncell-mediated immunityinfluenza virus infectionSARS-CoV-2 VOCsMHC-I upregulationclass I expressionSARS-CoV-2T cell recognitionvirus infectionMHC II expressionspike proteinenhanced inhibitioninfectioncell recognitioncommon mutationsreinfectionE proteinantibodiesviral genessubvariantsexpressionSARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox J, Lucas C, Yildirim I, Dai Y, Wang E, Monteiro V, Lord S, Carlin J, Kita M, Buckner J, Ma S, Campbell M, Ko A, Omer S, Lucas C, Speake C, Iwasaki A, Ring A. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nature Communications 2023, 14: 1299. PMID: 36894554, PMCID: PMC9996559, DOI: 10.1038/s41467-023-36686-8.Peer-Reviewed Original ResearchConceptsvaccine-associated myocarditisautoimmune patientsautoantibody reactivitySARS-CoV-2 mRNA vaccinationvaccine-related adverse effectsSARS-CoV-2 immunitySARS-CoV-2 infectionacute COVID-19development of autoantibodiesCOVID-19 patientsanti-viral immunityvirus-specific antibodiesCOVID-19 vaccineCOVID-19humoral autoimmunitymRNA vaccinationautoantibody responsepost vaccinationautoantibody developmentautoimmune diseaseshumoral responsehealthy individualspatientsantigen profilingadverse effects